Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 tat protein

AIDS Research and Human Retroviruses

Volumn 14, Issue 17, 1998, Pages 1561-1571

  Corallini, Alfredo ^a   Betti, Monica ^a   Rusnati, Marco ^b   Campioni, Diana ^a   Ciomei, Marina ^c   Sola, Francesco ^c   Calza, Nilla ^a   Zauli, Giorgio ^a   Presta, Marco ^b   Barbanti Brodano, Giuseppe ^a   Caputo, Antonella ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,7 [CARBONYL BIS[IMINO N METHYL 4,2 PYRROLECARBONYLIMINO (N METHYL 4,2 PYRROLE)CARBONYLIMINO]] BIS(1,3 NAPHTHALENE DISULFONATE); DISTAMYCIN A DERIVATIVE; PNU 153429; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032553604     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.1561     Document Type: Article

References (46)

1. Arya SK, Guo C, Josephs SF, and Wong-Staal F: Transactivator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985;229:69-73.
2. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC, and Wong-Staal F: The trans-activator gene of HTLV-III is essential for virus replication. Nature (London) 1986;320:367-371.
3. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, and Gallo RC: Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-287.
4. Ensoli B, Barillari G, Salahuddin ZS, Gallo RC, and Wong-Staal F: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (London) 1990;345:84-86.
5. Milani D, Zauli G, Neri LM, Marchisio M, Previati M, and Capitani S: Influence of the human immunodefiency virus type 1 Tat protein on the proliferation and differentiation of PC12 rat pheochromocytoma cells. J Gen Virol 1993;74:2587-2594.
6. Zauli G, Gibellini D, Milani D, Mazzoni M, Borgatti P, La Placa M, and Capitani S: Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. Cancer Res 1993;53:4481-4485.
7. Viscidi RP, Mayur K, Lederman HM, and Frankel AD: Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989;216:1606-1608.
8. Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, and Barbanti-Brodano G: HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retroviruses 1995;11:1039-1048.
9. Barillari G, Buonaguro L, Fiorelli V, Hoffman J, Michaels F, Gallo RC, and Ensoli B: Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implication for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992;149: 3727-3734.
10. Barillari G, Gendelman R, Gallo RC, and Ensoli B: The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RDG amino acid sequence. Proc Natl Acad Sci USA 1993;90:7941-7945.
11. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, and Stetler-Stevenson WG: Angiogenic potential in vivo by Kaposi's sarcoma cell-free supematants and HIV-1 tat product: Inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994;8:1237-1244.
12. Albini A, Barillari G, Benelli R, Gallo RC, and Ensoli B: Tat, the human immunodeficiency virus type 1 regulatory protein, has angiogenic properties. Proc Natl Acad Sci USA 1995;92:4838-4842.
13. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, and Jay G: The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature (London) 1988;335:606-611.
14. Corallini A, Altavilla G, Pozzi L, Bignozzi F, Negrini M, Rimessi P, Gualandi F, and Barbanti-Brodano G: Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different hystotypes. Cancer Res 1993;53: 5569-5575.
15. Zauli G, La Placa M, Vignoli M, Re MC, Gibellini D, Furlini G, Milani D, Marchisio M, Mazzoni M, and Capitani S: An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently tat-transfected cells and required for optimal human immunodeficiency virus type-1 long terminal repeat transactivating activity. J AIDS 1995;10:306-316.
16. Corallini A, Campioni D, Rossi C, Albini A, Possati L, Rusnati M, Gazzanelli G, Benelli R, Masiello L, Sparacciari V, Presta M, Mannello F, Fontanini G, and Barbanti-Brodano G: Promotion of tumor metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS 1996;10: 701-710.
17. Burgess WH and Maciag T: The heparin binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989;58: 575-581.
18. Folkman J and Klagsbrun M: Angiogenic factors. Science 1987; 235:442-447.
19. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady J, and Gallo RC: Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature (London) 1994;371:674-680.
20. Brem SS, Gullino PM, and Medina D: Angiogenesis: A marker for neoplastic transformation of mammary capillary hyperplasia. Science 1977;195:880-882.
21. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
22. Folkman J: Tumor angiogenesis and tissue factor. Nature Med 1996;2:167-168.
23. Stein CA, La Rocca RV, Thomas R, McAtee N, and Meyers CE: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499-508.
24. Myers CE, La Rocca RV, Stein CA, Cooper MR, Dawson N, Choyke P, Linehan M, and Uhrich M: Treatment of hormonally refractory prostate cancer with suramin. Proc Am Soc Clin Oncol 1990;9:133-141.
25. La Rocca RV, Myers CE, Stein CA, Cooper MR, and Uhrich M: Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy. Proc Am Soc Clin Oncol 1990;9: 1041-1049.
26. Pesenti E, Sola F, Mongelli N, Grandi M, and Spreafico F: Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992;66: 367-372.
27. Gagliardi A, Hadd H, and Collins DC: Inhibition of angiogenesis by suramin. Cancer Res 1992;52:5073-5075.
28. Ciomei M, Pastori W, Mariani M, Sola F, Grandi M, and Mongelli N: New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol 1994;47:295-302.
29. Sola F, Farao M, Ciomei M, Pastori A, Mongelli N, and Grandi M: FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metastasis 1995;15:222-231.
30. Wright CM, Felber BK, Paskalis H, and Pavlakis GN: Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science 1986;234:988-992.
31. Saito A, Seiler S, Chu A, and Fleischer S: Preparation and morphology of sarcoplasmic reticulum terminal cisternae from rabbit skeletal muscle. J Cell Biol 1984;99:875-885.
32. Demarchi F, d'Adda di Fagagna F, Falaschi A, and Giacca M: Activation of transcription factor NF-κB by the Tat protein of human immunodeficiency virus type-1. J Virol 1996;70:4427-4437.
33. Gorman CM, Moffat LF, and Howard BH: Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982;2:1044-1051.
34. Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, Giacca M, Ciomei M, Corallini A, and Presta M: The basic domain in HIV-1 Tat protein as a target for polysulfated heparin-mimicking extracellular Tat antagonists. J Biol Chem 1998;273:16027-16037.
35. Albini A, Benelli R, Presta M, Rusnati M, Ziehe M, Rubartelli A, Paglialunga G, Bussolino F, and Noonan D: HIV-Tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996;12:289-297.
36. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D, di Fagagna F, Giacca M, and Presta M: Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfaction and size. J Biol Chem 1997;272:11313-11320.
37. Jones KA and Peterlin MB: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994;63:717-738.
38. Westendrop MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, and Krammer PH: Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat protein and gp120. Nature (London) 1995;375:497-500.
39. Vogel J, Hinrichs SH, Napolitano LA, Ngo L, and Jay G: Liver cancer in transgenic mice carrying the human immunodeficiency virus tat gene. Cancer Res 1991;51:6686-6690.
40. Zauli G and Gibellini D: The human immunodeficiency virus type-1 (HIV-1) Tat protein and Bcl-2 gene expression. Leukemia Lymphoma 1996;23:551-560.
41. Possati L, Campioni D, Sola F, Leone L, Ferrante L, Trabanelli C, Ciomei M, Montesi I, Rocchetti R, Bompadre S, Barbanti-Brodano G, Caputo A, and Corallini A: Antiangiogenic, antitumoral and antimetastatic effects of two distamycin A derivatives with anti-HIV 1 Tat activity in a Kaposi's sarcoma-like murine model. Submitted (1998).
42. Frankel AD and Pabo CO: Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988;55:1189-1193.
43. Re MC, Furlini G, Vignoli M, Ramazzotti E, Roderigo G, De Rosa V, Zauli G, Lolli S, Capitani S, and La Placa M: Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquired Immune Defic Syndr Hum Retroviruses 1995;10:408-416.
44. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, and Capitani S: Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 1996;271:22961-22964.
45. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, and Pardee AB: Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997;94:8116-8120.
46. Huang L, Joshi A, Willey R, Orenstein J, and Jeang KT: Human immunodeficiency viruses regulated by alternative trans-activators: Genetic evidence for a novel non-trascriptional function of Tat in virion infectivity. EMBO J 1994;2886-2893.